Aspergillosis includes a wide spectrum of diseases caused by fungi of the genus Aspergillus with clinical manifestations that range from colonization (e.g., aspergilloma), to allergic bronchopulmonary aspergillosis, to disseminated forms of infection. Invasive aspergillosis (IA) has been estimated to occur in 10% of acute myeloid leukemia patients during post-induction aplasia or consolidation therapy and after 5–15% of allogeneic hematopoietic stem cell transplants (HSCT) [1,2]. Additional persons at risk for IA include recipients of solid organ transplants and patients with chronic granulomatous disease (CGD). Despite the significant progress attained in the management of this severe infection, its prevention, diagnosis, and therapy remain extremely difficult, rendering it a leading cause of death among immunocompromised patients. Additionally, concerns over antimold prescription and the remarkably high healthcare costs owing to its chronic course and mortality rates have been diverting clinicians from universal prophylaxis to risk stratification and preemptive approaches. This has inspired the search for novel individual prognostic factors, particularly genetic, to apply in the categorization of those most vulnerable to infection.

Human genetic susceptibility to invasive aspergillosis / Cunha, C; Aversa, Franco; Romani, L; Carvalho, A.. - In: PLOS PATHOGENS. - ISSN 1553-7374. - 9:8(2013). [10.1371/journal.ppat.1003434]

Human genetic susceptibility to invasive aspergillosis.

AVERSA, Franco;
2013-01-01

Abstract

Aspergillosis includes a wide spectrum of diseases caused by fungi of the genus Aspergillus with clinical manifestations that range from colonization (e.g., aspergilloma), to allergic bronchopulmonary aspergillosis, to disseminated forms of infection. Invasive aspergillosis (IA) has been estimated to occur in 10% of acute myeloid leukemia patients during post-induction aplasia or consolidation therapy and after 5–15% of allogeneic hematopoietic stem cell transplants (HSCT) [1,2]. Additional persons at risk for IA include recipients of solid organ transplants and patients with chronic granulomatous disease (CGD). Despite the significant progress attained in the management of this severe infection, its prevention, diagnosis, and therapy remain extremely difficult, rendering it a leading cause of death among immunocompromised patients. Additionally, concerns over antimold prescription and the remarkably high healthcare costs owing to its chronic course and mortality rates have been diverting clinicians from universal prophylaxis to risk stratification and preemptive approaches. This has inspired the search for novel individual prognostic factors, particularly genetic, to apply in the categorization of those most vulnerable to infection.
2013
Human genetic susceptibility to invasive aspergillosis / Cunha, C; Aversa, Franco; Romani, L; Carvalho, A.. - In: PLOS PATHOGENS. - ISSN 1553-7374. - 9:8(2013). [10.1371/journal.ppat.1003434]
File in questo prodotto:
File Dimensione Formato  
Cunha PLOS Path 2013..pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 138.6 kB
Formato Adobe PDF
138.6 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2678883
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 53
social impact